HPMA copolymer-DACH platinate

A second lead HPMA copolymer-platinate (AP5346) has been identified with a similar Gly-Phe-Leu-Gly-aminomalonate side chain, but in this case terminating in a 1,2-diaminocyclohexyl (DACH) palatinate (Fig. 8). hi Phase 1 clinical trial, it was administered as intravenous infusion of 80-1280 mg Pt/m once a week in 28-day cycle to patients with a broad cross-section of tumour types. Out of the 12 evaluable patients, one demonstrated a partial response. Dose hmiting toxicity was neutropenia but also nausea, vomiting, asthenia, fatigue and diarrhoea were observed (as presented in October 2004 at the 16th... 

---